Lab Manager | Run Your Lab Like a Business
Researchers sourced a molecule from Funnel Web spider venom which is showing promise to treat heart attacks
Institute for Molecular Bioscience, University of Queensland

Spider Venom Heart Drug a Step Closer

A spider venom molecule has met critical benchmarks towards becoming a treatment for heart attack

by University of Queensland
Register for free to listen to this article
Listen with Speechify
0:00
5:00

A spider venom molecule being investigated by a University of Queensland team has met critical benchmarks towards becoming a treatment for heart attack and stroke.

Associate professor Nathan Palpant and professor Glenn King from UQ’s Institute for Molecular Bioscience have previously shown that the drug candidate Hi1a protects cells from the damage caused by heart attack and stroke.

Get training in Lab Crisis Preparation and earn CEUs.One of over 25 IACET-accredited courses in the Academy.
Lab Crisis Preparation Course

Palpant said a subsequent study has put the drug through a series of preclinical tests designed to mimic real-life treatment scenarios.

“These tests are a major step towards helping us understand how Hi1a would work as a therapeutic—at what stage of a heart attack it could be used and what the doses should be,” Palpant said.

“We established that Hi1a is as effective at protecting the heart as the only cardioprotective drug to reach Phase 3 clinical trials, a drug that was ultimately shelved due to side effects. Importantly, we found that Hi1a only interacts with cells in the injured zone of the heart during an attack and doesn’t bind to healthy regions of the heart—reducing the chance of side effects.”

King, who recently won the Prime Minister’s Prize for Innovation for developing the world’s first insecticides from spider venom, discovered Hi1a in the venom of the K’gari funnel web spider.

“Hi1a could reduce damage to the heart and brain during heart attacks and strokes by preventing cell death caused by lack of oxygen,” King said.

“Our testing and safety studies from independent contract research organizations has provided evidence that Hi1a could be an effective and safe therapeutic.”

Infensa Bioscience, a company co-founded by the researchers, raised $23 million in 2022 to develop Hi1a for commercial purposes.

Infensa CEO and UQ researcher, associate professor Mark Smythe, said cardiovascular disease is the leading cause of death globally.

“Most deaths from cardiovascular disease are caused by heart attacks and strokes, yet there are no drugs on the market that prevent the damage they cause,” Smythe said.

“An effective drug to treat heart attacks would have worldwide impact, providing a breakthrough to improve the lives of millions of individuals living with heart disease.”

The research team included Dr. Meredith Redd from IMB as well as Dr. Melissa Reichelt and Dr. Yusuke Yoshikawa from UQ’s School of Biomedical Sciences.

- This press release was originally published on the University of Queensland website